Background and objectives: Surgery is the primary therapy for localized gastric
cancer, but even with the best results only 40% 5-year survival can be
achieved with the use of postoperative adjuvant chemoradiotherapy. Preoperative
therapy might help increase the R0 resection rate, which is an independent
predictor of 5-year OS. Our study hypothesized that the concurrent
combination of carboplatin-paclitaxel with radiation therapy would result in a
pathological CR rate, which will be in turn associated with OAS and DFS benefits.
Patients and methods: prospective phase II study included 32 patients
with locally advanced gastric adenocarcinoma including gastroesophageal
junction who received a combination of neoadjuvant conformal radiotherapy
concurrently with carboplatin-paclitaxel followed by surgery. Results: Pathological
CR and R0 resection rates were 18.8% and 75% respectively. With a
median follow up of 24 months, 2 years disease-free survival was 28.1% and
overall survival was 51.3%. The regimen was tolerated with neither grade 4
toxicities nor deaths. Conclusion: Neoadjuvant radiotherapy concomitant
with carboplatin-paclitaxel chemotherapy is a well-tolerated approach for patients
with locally advanced gastric adenocarcinoma resulting in significant
pathological CR and R0 resection margins as reflected by the good DFS and
OS.
Research Member
Research Department
Research Year
2018
Research Journal
Journal of Cancer Therapy
Research Publisher
NULL
Research Vol
Vol. 9
Research Rank
1
Research_Pages
pp. 503-515
Research Website
NULL
Research Abstract